

Dr Rowena Mobbs, neurologist:

"Novel studies like this have their place, and funding for exploratory studies is vital. But this is only phase 2 of a 4 phase process, so it would be years before results relevant to patient care are seen."

"Theoretically, it is a promising line of research to explore, but current techniques to understand microscopic brain changes during concussion are questionable. You can measure symptoms, but you may not know the true underlying cell changes."

"Like all exploratory research, the risks could outweigh the benefits, and this is why the study would carefully monitor safety data at this stage."

"The road to a clinically useful drug is long and difficult. This is a phase 2 study, however only a small percentage of drugs reach the market. Understanding if this truly is a breakthrough will take years."

"Keeping a balance of optimism with caution is vital when reporting on any new medication. We are far from a breakthrough medication for concussion but we hope for such a drug. Balanced journalism should report findings with caution."